A detailed history of Vr Adviser, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Vr Adviser, LLC holds 3,882,709 shares of VRDN stock, worth $76.4 Million. This represents 9.15% of its overall portfolio holdings.

Number of Shares
3,882,709
Previous 3,882,671 -0.0%
Holding current value
$76.4 Million
Previous $50.5 Million 74.87%
% of portfolio
9.15%
Previous 5.54%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.16 - $23.33 $462 - $886
38 Added 0.0%
3,882,709 $88.3 Million
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $820 - $1,143
48 Added 0.0%
3,882,671 $68 Million
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $8.9 Million - $18 Million
800,001 Added 25.95%
3,882,623 $84.6 Million
Q2 2023

Aug 11, 2023

BUY
$22.57 - $29.67 $8.64 Million - $11.4 Million
382,757 Added 14.18%
3,082,622 $73.3 Million
Q4 2022

May 15, 2023

BUY
$18.78 - $29.74 $10.7 Million - $16.9 Million
569,557 Added 26.74%
2,699,865 $78.9 Million
Q4 2022

Feb 14, 2023

BUY
$18.78 - $29.74 $10.7 Million - $16.9 Million
569,557 Added 26.74%
2,699,865 $78.9 Million
Q3 2022

May 15, 2023

BUY
$10.7 - $25.5 $2.97 Million - $7.07 Million
277,389 Added 14.97%
2,130,308 $43.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $2.97 Million - $7.07 Million
277,389 Added 14.97%
2,130,308 $43.7 Million
Q2 2022

May 15, 2023

SELL
$9.55 - $19.0 $8.09 Million - $16.1 Million
-846,946 Reduced 31.37%
1,852,919 $21.4 Million
Q4 2021

Feb 14, 2022

BUY
$15.65 - $21.5 $28.7 Million - $39.4 Million
1,833,424 Added 9404.59%
1,852,919 $36.6 Million
Q4 2020

Feb 12, 2021

BUY
$7.28 - $21.0 $141,923 - $409,395
19,495 New
19,495 $321,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $785M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Vr Adviser, LLC Portfolio

Follow Vr Adviser, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vr Adviser, LLC with notifications on news.